The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review.
Mansour TobaiqyNawal HelmiKathrine MaclureSylvia SaadePublished in: International journal of clinical pharmacy (2023)
High frequency of mild and severe hepatotoxicity, associated with imatinib in CML patients, was reported in the published literature. Low numbers of mild and manageable thyroid toxicity events were reported.
Keyphrases
- high frequency
- chronic myeloid leukemia
- transcranial magnetic stimulation
- end stage renal disease
- ejection fraction
- oxidative stress
- newly diagnosed
- systematic review
- drug induced
- risk factors
- prognostic factors
- bone marrow
- acute myeloid leukemia
- dendritic cells
- early onset
- randomized controlled trial
- combination therapy